CCL2 and metabolic dysfunction-associated steatohepatitis: On the contrary, CCL2 showed no differences after IL-1β treatment (Fig 7F), but its basal secretion in HSCs from NASH-affected liver was significantly increased compared to control (Fig 7F), suggesting that HSCs from NASH-affected livers are already sensitized for CCL2 secretion.